Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594547 | 0.78 | TSHR (0.33) | TSHRTDP1ALDH1A1 | |
| SCHEMBL4275338 | 0.77 | PIK3CD (0.39) | MAPK1 | |
| SCHEMBL8962264 | 0.76 | TSHR (0.43) | TSHR | |
| SCHEMBL4235510 | 0.74 | MAPK1 (0.36) | MAPK1TSHRTDP1ALDH1A1 | |
| SCHEMBL925732 | 0.74 | MAPK1 (0.36) | MAPK1TSHRTDP1ALDH1A1 | |
| SCHEMBL23419900 | 0.74 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL14492467 | 0.74 | LMNA (0.38) | TDP1ALDH1A1 | |
| SCHEMBL26955508 | 0.74 | TSHR (0.36) | TSHR | |
| SCHEMBL18354297 | 0.72 | ALDH1A1 (0.33) | MAPK1TSHRALDH1A1 | |
| SCHEMBL18135504 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | MAPK1 2398/4885TSHR 933/4885TDP1 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.